An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Launched by SAREPTA THERAPEUTICS, INC. · May 10, 2018
Trial Information
Current as of May 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
- • Is between 7 and 23 years of age, inclusive, at enrollment.
- • Other inclusion/exclusion criteria apply.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a leading biopharmaceutical company focused on developing innovative genetic medicines to transform the treatment of rare diseases, particularly those caused by genetic mutations. With a strong emphasis on advancing therapies for Duchenne muscular dystrophy (DMD) and other neuromuscular disorders, Sarepta utilizes cutting-edge technologies, including gene therapy and RNA-targeted approaches, to address unmet medical needs. The company is committed to rigorous clinical research and collaboration with the scientific community to deliver safe and effective treatment options, ultimately aiming to enhance the quality of life for patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Ottawa, Ontario, Canada
Saint Louis, Missouri, United States
Cincinnati, Ohio, United States
Los Angeles, California, United States
Baltimore, Maryland, United States
Houston, Texas, United States
Pittsburgh, Pennsylvania, United States
Newcastle Upon Tyne, , United Kingdom
Los Angeles, California, United States
Boston, Massachusetts, United States
Barcelona, , Spain
Leuven, , Belgium
Valencia, , Spain
Calgary, Alberta, Canada
Praha 5, , Czechia
San Diego, California, United States
Liverpool, , United Kingdom
Portland, Oregon, United States
Norfolk, Virginia, United States
Phoenix, Arizona, United States
Petach Tikva, , Israel
Essen, Nordrhein Westfalen, Germany
Dallas, Texas, United States
Gent, Oost Vlaanderen, Belgium
Las Vegas, Nevada, United States
Chicago, Illinois, United States
Gulf Breeze, Florida, United States
Warsaw, Mazowieckie, Poland
London, , United Kingdom
Atlanta, Georgia, United States
Palo Alto, California, United States
Gainesville, Florida, United States
Iowa City, Iowa, United States
Rochester, New York, United States
Columbus, Ohio, United States
Salt Lake City, Utah, United States
Milwaukee, Wisconsin, United States
Sofia, , Bulgaria
Brno, , Czechia
Nantes Cedex, , France
Paris, , France
Freiburg, Baden Wurttemberg, Germany
Genova, Liguria, Italy
Cona, , Italy
Milano, , Italy
Gdansk, , Poland
Barcelona, Cataluña, Spain
Goteborg, , Sweden
Leeds, , United Kingdom
Milwaukee, Wisconsin, United States
Patients applied
Trial Officials
Medical Director
Study Director
Sarepta Therapeutics, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials